Skip to content
Screener

Beta Bionics BBNX Debt-to-equity

Debt-to-equity at other companies

Insulet logo
InsuletPODD
0.7×-0.6×
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
5.7×+2.3×
Medtronic logo
MedtronicMDT
0.6×0.0×
AdaptHealth logo
AdaptHealthAHCO
1.3×0.0×
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
15.2×+10.6×

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S6×-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%—
Current ratio8.9×-5.8×

Where this comes from

Calculated from Beta Bionics’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026. Open the filing →

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777

FAQ

What is Beta Bionics's debt-to-equity?
Beta Bionics (BBNX) reported debt-to-equity of 0× in Q2 2026.
How has Beta Bionics's debt-to-equity changed year-over-year?
Beta Bionics's debt-to-equity increased by 14.4% year-over-year, from 0× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Beta Bionics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude